First occurrence of a Hymenosomatid crab <i>Elamena mathoei</i> (Desmarest, 1823) (Crustacea: Decapoda: Brachyura) in the Mediterranean Sea

Mediterranean fauna is undergoing drastic modifications as a result of anthropogenic activities and global warming. The most important of these is the colonization of the Mediterranean Sea by alien species, many of them entering through the Suez Canal. While many of them are still confined to the Levant Basin, several have extended their distribution westwards to Tunisian waters. The presence of the Indo-west Pacific hymenosomatid crab Elamena mathoei on a rocky shore at Sidi Daoud, Cape Bon Peninsula, Tunisia, is the first Mediterranean record of this species. It is a testimony to the changes in the patterns of invasion in the Mediterranean Sea

First occurrence of a Hymenosomatid crab Elamena mathoei (Desmarest, 1823) (Crustacea: Decapoda: Brachyura) in the Mediterranean Sea

Mediterranean fauna is undergoing drastic modifications as a result of anthropogenic activities and global warming. The most important of these is the colonization of the Mediterranean Sea by alien species, many of them entering through the Suez Canal. While many of them are still confined to the Levant Basin, several have extended their distribution westwards to Tunisian waters. The presence of the Indo-west Pacific hymenosomatid crab Elamena mathoei on a rocky shore at Sidi Daoud, Cape Bon Peninsula, Tunisia, is the first Mediterranean record of this species. It is a testimony to the changes in the patterns of invasion in the Mediterranean Sea

Study protocol: NITric oxide during cardiopulmonary bypass to improve Recovery in Infants with Congenital heart defects (NITRIC trial): a randomised controlled trial

Introduction Congenital heart disease (CHD) is a major cause of infant mortality. Many infants with CHD require corrective surgery with most operations requiring cardiopulmonary bypass (CPB). CPB triggers a systemic inflammatory response which is associated with low cardiac output syndrome (LCOS), postoperative morbidity and mortality. Delivery of nitric oxide (NO) into CPB circuits can provide myocardial protection and reduce bypass-induced inflammation, leading to less LCOS and improved recovery. We hypothesised that using NO during CPB increases ventilator-free days (VFD) (the number of days patients spend alive and free from invasive mechanical ventilation up until day 28) compared with standard care. Here, we describe the NITRIC trial protocol. Methods and analysis The NITRIC trial is a randomised, double-blind, controlled, parallel-group, two-sided superiority trial to be conducted in six paediatric cardiac surgical centres. One thousand three-hundred and twenty infants <2 years of age undergoing cardiac surgery with CPB will be randomly assigned to NO at 20 ppm administered into the CPB oxygenator for the duration of CPB or standard care (no NO) in a 1:1 ratio with stratification by age (<6 and ≥6 weeks), single ventricle physiology (Y/N) and study centre. The primary outcome will be VFD to day 28. Secondary outcomes include a composite of LCOS, need for extracorporeal membrane oxygenation or death within 28 days of surgery; length of stay in intensive care and in hospital; and, healthcare costs. Analyses will be conducted on an intention-to-treat basis. Preplanned secondary analyses will investigate the impact of NO on host inflammatory profiles postsurgery. Ethics and dissemination The study has ethical approval (HREC/17/QRCH/43, dated 26 April 2017), is registered in the Australian New Zealand Clinical Trials Registry (ACTRN12617000821392) and commenced recruitment in July 2017. The primary manuscript will be submitted for publication in a peer-reviewed journal. Trial registration number ACTRN12617000821392.</p

Adolescents and adults with Fontan circulation:insights from the PREpArE-Fontan registry

The Patient Registry for Adolescents and Adults with Stable Fontan Circulation aims to describe a contemporary cohort of Fontan patients who could be eligible for a clinical trial investigating macitentan, an endothelin receptor antagonist. This international, non-interventional, multicentre, cross-sectional, observational registry enrolled patients with “stable” Fontan circulation ≥10 years following extra-cardiac conduit or lateral tunnel procedure. Main exclusion criteria were NYHA functional class IV, reoperation of Fontan circulation, or signs of disease worsening. Patient characteristics at enrolment are described; available data were collected during a single registration visit. Of the 266 screened patients, 254 were included in this analysis. At enrolment, median (interquartile range) age was 24 (20;30) years, 37%/63% of patients were from the USA/Europe, 54% were male, 54%/47% had undergone extra-cardiac conduit/lateral tunnel procedures, and 95% were in NYHA functional class I or II. History of arrhythmia was more common in older patients and patients with lateral tunnel; overall prevalence was 19%. Most laboratory values were within the normal range but mean creatinine clearance was abnormally low (87.7 ml/min). Angiotensin-converting enzyme inhibitors were used by 48% of patients and their use was associated with creatinine clearance &lt;90 ml/min (p = 0.007), as was Fontan completion at an older age (p = 0.007). 53.4% of patients had clinical characteristics that could potentially meet an endothelin receptor antagonist trial’s eligibility criteria. The PREpArE-Fontan registry describes a cohort of patients who could potentially participate in an endothelin receptor antagonist trial and identified early subtle signs of Fontan failure, even in “stable” patients

The Fontan epidemic: population projections from the Australia and New Zealand Fontan registry

Background: The number and age demographic of the future Fontan population is unknown

The macro- and megabenthic fauna on the continental shelf of the eastern Amundsen Sea, Antarctica

In 2008 the BIOPEARL II expedition on board of RRS James Clark Ross sailed to the eastern Amundsen Sea Embayment and Pine Island Bay, one of the least studied Antarctic continental shelf regions due to its remoteness and ice cover. A total of 37 Agassiz trawls were deployed at depth transects along the continental and trough slopes. A total of 5,469 specimens, belonging to 32 higher taxonomic groups and more than 270 species, were collected. Species richness per station varied from 1–55. The benthic assemblages were dominated by echinoderms and clearly different to those in the Ross, Scotia and Weddell seas. Here we present the macro- and megafaunal assemblage structure, its species richness and the presence of several undescribed species

Larval morphology of the family Parthenopidae, with the description of the megalopa stage of Derilambrus angulifrons (Latreille, 1825) (Decapoda: Brachyura), identified by DNA barcode

Although Parthenopidae is a brachyuran decapod family comprising almost 140 species, there is little knowledge about its larval morphology. There are only two complete larval developments reared in the laboratory and some larval stages described for seven species. In the present work these data are compared and analysed. A summary is made of the larval features that characterize parthenopids that can be used to distinguish them from other brachyuran larvae. In addition, the megalopa stage of Derilambrus angulifrons and Parthenopoides massena was collected from plankton and identified by DNA barcodes. The morphology of the megalopa of D. angulifrons is described for the first time, and that of P. massena is compared with a previous description